Research programme: somatostatin type 2 receptor antagonists - Zucara Therapeutics
Alternative Names: PRL-2903Latest Information Update: 28 Jul 2024
At a glance
- Originator Tulane University; University of Toronto; York University
- Developer Zucara Therapeutics
- Class Antihypoglycaemics; Peptides
- Mechanism of Action Somatostatin receptor 2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hypoglycaemia
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Hypoglycaemia in Canada (Intraperitoneal)
- 12 Jun 2020 Preclinical trials in Hypoglycaemia in Canada (Intraperitoneal)
- 12 Jun 2020 Preclinical pharmacokinetics and pharmacodynamics data presented at the 80th Annual Scientific Sessions of the American Diabetes Association (ADA-2020)